Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant interferon alfa-2
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular, Intravenous, Intralesional
01
Overview
Recombinant interferon alfa-2 is a synthetic form of the naturally occurring protein interferon alpha-2, produced via recombinant DNA technology in Escherichia coli[3][8]. It is a type I interferon with antitumor, antiviral, and immunomodulatory activity, acting mainly by inhibiting viral replication and tumor cell proliferation and modulating the host immune response[3][4][8]. This drug is indicated for the treatment of a wide range of diseases including chronic hepatitis B, chronic hepatitis C, hairy cell leukemia, follicular lymphoma, malignant melanoma, AIDS-related Kaposi sarcoma, and genital warts, and is being studied for additional cancers and viral diseases[1][4][5][7][8].
- Brand names
- Roferon-AIntron AHeberon Alfa R
- Other names
- recombinant interferon alfa-2arecombinant interferon alfa-2binterferon alpha-2ainterferon alpha-2brecombinant human interferon alpha-2
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on recombinant interferon alfa-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant interferon alfa-2.